Navidea Biopharmaceuticals, Inc. (NAVB)
OTCMKTS: NAVB · Delayed Price · USD
0.0005
+0.0004 (400.00%)
Jun 28, 2024, 9:59 AM EDT - Market closed

NAVB Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20222021202020192018 2017 - 1992
Net Income
-17.22-11.73-10.64-10.95-16.13
Upgrade
Depreciation & Amortization
0.10.080.070.140.15
Upgrade
Share-Based Compensation
0.30.470.230.230
Upgrade
Other Operating Activities
7.830.962.171.2120.25
Upgrade
Operating Cash Flow
-8.99-10.22-8.17-9.354.28
Upgrade
Operating Cash Flow Growth
-----92.76%
Upgrade
Capital Expenditures
-0.39-0.33-0.41-0.06-0.05
Upgrade
Acquisitions
00000.05
Upgrade
Change in Investments
----0.8-2.2
Upgrade
Other Investing Activities
--01.633.15
Upgrade
Investing Cash Flow
-0.39-0.33-0.410.770.95
Upgrade
Common Stock Issued
004.447.093
Upgrade
Share Repurchases
0-0.02000
Upgrade
Other Financing Activities
7.1412.095.77-0.93-7.55
Upgrade
Financing Cash Flow
7.1412.1110.216.16-4.55
Upgrade
Net Cash Flow
-2.241.561.62-2.430.68
Upgrade
Free Cash Flow
-9.38-10.55-8.59-9.414.23
Upgrade
Free Cash Flow Growth
-----92.84%
Upgrade
Free Cash Flow Margin
-14282.76%-1984.44%-938.53%-35357.39%1311.31%
Upgrade
Free Cash Flow Per Share
-0.32-0.36-0.36-0.650.50
Upgrade
Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.